🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — July 10, 2026

The July 10, 2026, digest reveals a market dominated by capital structure engineering and defensive maneuvers, with 50 filings showing a clear bias toward financial restructuring, M&A execution, and governance changes. A significant theme is the prevalence of going-concern risks and cash preservation strategies, highlighted by InnSuites Hospitality Trust's auditor change citing going concern, ZyVersa Therapeutics' cost-cutting measures including potential 'going dark,' and multiple companies (BSTR Holdings, Faraday Future) relying on dilutive financing to survive. Conversely, a few companies are executing growth strategies, such as DXP Enterprises expanding its credit facility by $40M after a period of strong sales growth (sales rising from $1.1B to $2.1B) and Nuveen Churchill Direct Lending upsizing its debt offering. M&A activity is mixed, with a high-value SPAC merger (RF Acquisition Corp III / HCC Healthcare at $500M pre-money) and a strategic pivot by Nu-Med Plus into gold mining, contrasted by the termination of exclusivity in the Coeptis/Skycore deal. Insider activity is limited but notable, with the CEO and CFO of iQSTEL receiving compensation increases and the executives of ZyVersa taking voluntary pay cuts, signaling divergent management confidence. The overall sentiment is cautious, with a heavy focus on liquidity management and structural changes to address stock price or operational challenges.

50 high priority 50 total filings
· daily

Insider Trading Pulse — July 10, 2026

Today's insider trading digest reveals a pronounced bearish tilt among senior insiders, with multiple C-suite officers executing significant sales, often under Rule 10b5-1 plans. The most material insider sales occurred at Aktis Oncology (CMO and COO sold ~$1.7M combined), Casey's General Stores (CFO sold $4.78M), and Insmed (Chair & CEO sold $583K). Notable director-level selling was seen at Hormel Foods ($495K) and United Therapeutics ($179K). The day was dominated by negative sentiment transactions, though several routine option exercises and tax-withholding filings were neutral. A positive signal emerged from Angel Oak Financial Strategies Income Term Trust, where a 10% owner purchased $40M in senior notes. The data suggests insider conviction is weakest in biotech and consumer staples, while capital allocation trends show continued share-based compensation and director awards across technology and healthcare sectors.

50 high priority 50 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 10, 2026

All four filings in this digest are Nasdaq-listed companies receiving non-compliance or delisting notices, underscoring a concentrated wave of distress among micro-cap and small-cap issuers. GeoVax Labs, NanoVibronix, Lakeside Holding, and Mercer International each face minimum bid price or stockholders' equity violations, with NanoVibronix at the highest risk due to a prior reverse split that disqualifies it from a standard cure period. Lakeside Holding has already received a second 180-day extension, indicating persistent price weakness. No period-over-period financial data, insider activity, capital allocation, or forward-looking guidance was disclosed in these 8-K filings, limiting quantitative trend analysis. The overarching theme is a liquidity and market confidence crisis, with no clear catalysts for recovery and a high probability of at least one delisting event. Investors should monitor these names for potential bankruptcy or going-concern triggers as they exhaust compliance remedies.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — July 10, 2026

The July 10, 2026, filing batch reveals a pronounced wave of negative corporate actions, with a cluster of delistings (7 filings) and insolvency updates (5 filings) dominating the high-priority event landscape. A significant trend is the surge in SPAC activity, including a major valuation reduction in a pending merger (Plum Acquisition Corp IV cutting its target valuation by 30% to $3.15B) and multiple SPACs extending deadlines or completing IPOs, signaling both opportunity and distress in the blank-check sector. The healthcare and life sciences sector is a focal point for M&A, with GSK's $124/share tender offer for Nuvalent clearing its HSR waiting period and a $500M pre-money SPAC merger for HCC Healthcare. Financial distress is evident across several small-cap companies, with 4 Nasdaq non-compliance/delisting notices and a major fraud declaration by IREDA against Gensol Engineering for ₹672.74 Crore. From a period-over-period perspective, Rotographics' target Teneron showed an 11.3% YoY revenue decline, while Brandywine's office disposition removed $4.7M in quarterly revenue, highlighting asset-level pressure in commercial real estate. Insider activity is limited in this batch, but capital allocation patterns show a mix of strategic M&A, debt financing for acquisitions, and balance sheet restructuring through share cancellations and stock splits.

48 high priority 48 total filings
· daily

US SEC Filings Daily Market Digest — July 10, 2026

Today's filings reveal a market bifurcated between aggressive capital deployment and significant corporate restructuring. The standout event is SK hynix's massive $26.5 billion U.S. IPO, signaling strong demand for AI-related semiconductor exposure. Concurrently, we see a wave of SPAC activity with several transactions (RF Acquisition Corp III, BSTR Holdings, Eureka Acquisition) progressing, though many are renegotiating terms, indicating a maturing SPAC market. Capital return programs are active, with News Corp and Mission Produce executing buybacks, while DXP Enterprises and EquipmentShare are expanding credit facilities and raising guidance, pointing to operational confidence. However, significant risk is present: Zoomcar's massive potential dilution from a proposed 2 billion share increase, Outlook Therapeutics' precarious Nasdaq compliance, and InnSuites' going concern warning highlight ongoing distress in smaller caps. The period-over-period data shows strong growth in semiconductor (ChipMOS +37% YoY) and industrial (DXP sales nearly doubled from 2021 to 2026) sectors, while Ares Management's preliminary estimate of a tripling in performance income underscores robust alternative asset management trends. Insider activity is limited, but the sheer volume of capital markets activity (IPOs, debt offerings, SPAC mergers) suggests a high conviction environment for dealmakers.

13 high priority 37 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 10, 2026

The 7 filings from the S&P 500 Consumer Discretionary sector reveal a mixed picture dominated by routine insider transactions and a key executive appointment. Lowe's Companies shows a pattern of director compensation via phantom stock awards, indicating standard retention practices rather than any strategic signal. DoorDash presents a more notable event with its CFO executing a significant stock sale (~$786K) under a 10b5-1 plan, which, while pre-planned, still warrants attention given the size relative to holdings. O'Reilly Automotive's appointment of a new Chief Supply Chain Officer from outside the company suggests a strategic focus on supply chain optimization, a critical area for auto parts retailers. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity were present in these filings, limiting the depth of trend analysis. The overall sentiment is neutral to slightly negative, with the DoorDash insider sale being the most material event. The sector appears to be in a steady-state phase with no major disruptions or catalysts emerging from this batch of filings.

7 high priority 7 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 10, 2026

The three filings from the S&P 500 Healthcare stream reveal a bifurcated insider activity pattern within the medical technology and biotechnology sectors. Edwards Lifesciences shows a clear divergence: a senior TAVR executive executed a planned sale following option exercise, while the new CFO received a substantial equity grant, signaling confidence in leadership transition. Moderna's director compensation via stock options and RSUs aligns with standard retention practices but offers no new directional signal. No period-over-period financial trends, forward-looking guidance, or capital allocation data were present in these filings, limiting portfolio-level trend synthesis. The key takeaway is the need to monitor Edwards' TAVR segment for potential insider sentiment shifts and to watch for upcoming earnings calls for operational context. Overall, the filings suggest stable governance but no immediate bullish or bearish catalysts from insider activity alone.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — July 10, 2026

The 11 filings for the period ending July 10, 2026, reveal a bifurcated market where a few large-cap companies like Delta Air Lines are experiencing strong top-line growth but significant margin compression due to surging input costs (fuel up 67% YoY), while a cluster of micro-cap and pre-revenue companies show nascent signs of revenue generation and cost control, albeit from extremely low bases. A dominant theme is the prevalence of going-concern risks and reliance on non-recurring gains, with 4 out of 11 companies (Radiant Strategies, Lottery.com, Sentinel Holdings, EvoAir) reporting accumulated deficits or negative equity. Insider trading activity was notably absent across all filings, which is a neutral signal but removes a key sentiment gauge. Capital allocation is minimal, with no dividends or buybacks reported, and most companies are in cash preservation or capital-raising modes. The most actionable intelligence comes from the stark contrast between Delta's operational scale and the micro-cap turnaround stories, where the latter show potential for significant revenue growth but carry extreme balance sheet risk.

11 high priority 11 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 10, 2026

This digest of 7 proxy filings reveals a governance landscape dominated by routine director elections and auditor ratifications, but with several high-materiality events that demand investor attention. The most significant development is Modine Manufacturing's pending Reverse Morris Trust transaction with Gentherm, which will reshape its corporate structure and trigger executive departures, including the retirement of Climate Solutions President Eric McGinnis. Aardvark Therapeutics stands out with a potentially dilutive stock option repricing proposal that could signal management's attempt to retain talent or align incentives after a period of underperformance. Lion Copper & Gold's proposed 20:1 to 30:1 share consolidation and quorum increase suggest the company is addressing a low stock price and potential governance vulnerabilities. Insider ownership data from Nexalin Technology shows concentrated insider control at 16.94%, while Dynatrace and Elite Express present standard governance proposals with no material financial disclosures. The overall theme is one of corporate restructuring and governance adjustments, with Modine and Aardvark presenting the most actionable insights for investors.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 10, 2026

The IPO pipeline on July 10, 2026, is dominated by a wave of S-1 filings from companies in transition—reverse mergers, SPAC combinations, and pivots into digital assets and AI—rather than traditional growth IPOs. A clear theme is the prevalence of resale registrations (6 of 11 filings) that offer no primary capital to issuers, creating significant share overhang and dilution risk for investors. Period-over-period data reveals a stark contrast: Apnimed's revenue surged 2,636% YoY from a related-party deal, while Holtec Nuclear saw a 7.0% revenue decline and a $23.7M operating loss at its Palisades segment. Capital allocation is uniformly non-existent, with no dividends or buybacks across the cohort, and insider activity is absent from all filings. The most critical development is the convergence of digital asset strategies—Avalanche Treasury (SPAC + crypto) and iPower (bitcoin/ethereum treasury)—signaling a new wave of crypto-exposed public entities, albeit with pre-revenue or untested models. Overall, the pipeline is heavy on risk and dilution, with few clear bullish catalysts, making selective, catalyst-driven scrutiny essential.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — July 10, 2026

On July 10, 2026, four micro-cap companies filed 8-Ks disclosing Nasdaq non-compliance, creating a concentrated wave of delisting risk in the small-cap space. All four filings are negative in sentiment, with materiality scores ranging from 8/10 to 9/10, signaling a systemic pattern of distress among low-priced equities. GeoVax Labs (GOVX) faces a stockholders' equity deficiency, while NanoVibronix (FEED), Lakeside Holding (LSH), and Mercer International (MERC) all violate the minimum $1.00 bid price rule. Notably, NanoVibronix is ineligible for the standard 180-day cure period due to a prior reverse split, making it the most acute risk. The concentration of these filings on a single day suggests a potential Nasdaq compliance sweep or broader market pressure on micro-cap stocks. No period-over-period financial trends, insider activity, or capital allocation data were available in these filings, limiting quantitative cross-comparison but highlighting the purely regulatory nature of the risk. The key market implication is a potential wave of delistings that could compress valuations across the micro-cap sector and trigger forced selling by index funds.

4 high priority 4 total filings
· daily

US Executive Officer Management Changes SEC — July 10, 2026

The 32 filings for July 10, 2026, reveal a heightened period of executive and director turnover across US-listed companies, with 14 departures or resignations and 10 appointments or transitions. The most critical development is at ZyVersa Therapeutics, where the CEO and CFO are taking voluntary pay cuts and the company is exploring a 'going dark' strategy, signaling severe financial distress. Ategrity Specialty Insurance stands out with a positive signal, pre-announcing record Q2 results with >22% YoY growth and a new CFO appointment. The period-over-period comparisons are limited in these filings, but the data shows a clear pattern of leadership instability in small-cap and micro-cap companies, with several departures citing personal reasons or planned transitions. Insider activity is minimal, but the compensation changes at KBR and Team Inc. indicate a focus on retention and severance adjustments. Overall, the digest highlights a cautious environment with pockets of opportunity in companies like Ategrity and Axon Enterprise, which are strengthening their boards with experienced executives.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 10, 2026

The July 10, 2026, board room change digest reveals a period of significant leadership transition across 32 US-listed companies, with a notable concentration of CFO and C-suite departures and appointments. The most critical development is the severe financial distress at **ZyVersa Therapeutics**, where a director resigned and management is considering going dark, divesting assets, and cutting headcount. Conversely, **Ategrity Specialty Insurance** provides a strong counterpoint, pre-announcing record Q2 results with >22% premium growth and >75% net income growth, alongside a CFO transition. A pattern of planned retirements and transitions is evident at **Adient**, **Sterling Infrastructure**, and **Lee Enterprises**, while companies like **KBR** and **Team Inc.** are proactively adjusting executive severance policies. The data shows a mix of routine board refreshment (e.g., **Alpha & Omega**, **Axon Enterprise**) and more disruptive changes, such as the sudden resignation of **Lands' End's** top legal and licensing executive. Overall, the period is characterized by high leadership fluidity, with a few filings signaling deep operational or financial challenges that warrant close monitoring.

32 high priority 32 total filings
· daily

USA Insider Trading Pulse — July 10, 2026

Today's insider trading pulse reveals a pronounced bearish tilt, with 11 filings showing negative sentiment from direct sales by senior executives, including C-suite officers at Aktis Oncology, Tempus AI, JFrog, and Insmed. A notable cluster of option exercises paired with immediate stock sales—particularly at Aktis Oncology and Insmed—suggests opportunistic profit-taking rather than a loss of confidence in the business. In contrast, the data shows a significant volume of neutral insider activity, primarily director stock awards and option grants at Planet Labs PBC and Seres Therapeutics, indicating routine compensation rather than conviction buying. A single positive signal stands out: a $40 million debt purchase by a 10% owner at Angel Oak Financial Strategies Income Term Trust, implying strong institutional confidence. Period-over-period comparisons were not available in the filings, limiting trend analysis, but the aggregate insider selling value exceeds $10 million, concentrated in healthcare and technology. The absence of forward-looking guidance or capital allocation changes in the filings suggests a quiet period for most companies, making the insider sales the primary actionable signal.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 10, 2026

The July 10, 2026, filings reveal a bifurcated M&A landscape: large-scale SPAC mergers are being renegotiated downward (Plum/CTR valuation cut ~30%), while smaller SPACs struggle to find targets (Quetta extends for the third time). The most significant sector theme is the aggressive pivot into critical minerals and energy transition assets, with two major lithium-focused SPAC deals (Constellation/HiTech and Plum/CTR) and a gold acquisition by a medical device company (Nu-Med Plus). Capital markets remain open for new SPAC IPOs (Viking and Meridian3 raised $431M combined), but the high number of extensions and valuation resets suggests investor skepticism. The most actionable signal is the Brandywine office disposition, which provides a clean comp for Austin office valuations at ~$733/sq ft. Insider activity is notably absent across all filings, which is a neutral signal but warrants monitoring for post-deal insider transactions. The forward-looking catalyst calendar is rich, with three key dates in the next two weeks: the Constellation/HiTech virtual investor event (July 16), the BurTech unit separation (July 14), and the Quetta extension deadline (August 10).

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 10, 2026

Overnight filings reveal a bifurcated market with aggressive capital deployment in AI infrastructure and semiconductor IPOs contrasting with persistent distress signals in small-cap biotech and real estate. The $26.5B SK hynix IPO dominates, signaling strong investor appetite for AI-related hardware, while EquipmentShare's raised guidance and $500M buyback authorization underscore robust demand in the equipment rental sector. However, multiple small-cap companies (InnSuites, Outlook Therapeutics) face going-concern and delisting risks, and insider selling at Hinge Health and United Therapeutics raises caution. A notable pattern is the surge in capital allocation actions—buybacks, credit facility expansions, and SPAC-related financings—indicating companies are positioning for growth or restructuring. The period-over-period data reveals strong revenue growth at ChipMOS (37.2% YoY) and DXP Enterprises (sales doubling to $2.1B), while Ares Management's preliminary performance income estimate of >$50M (vs $16M YoY) signals a potential inflection in alternative asset manager earnings.

22 high priority 28 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — July 09, 2026

This digest covers $134.3 million in federal construction and infrastructure contracts awarded entirely by civilian agencies (0% defense), with the Department of the Interior accounting for $76.0 million (57%) of the total via two large awards to Blinderman Construction Co Inc and Weeks Marine Inc. The highest-conviction signal is the $38.6 million Blinderman Construction contract for National Park Service cabin and lodge rehabilitation, which is fully funded with $38.2 million already outlayed, indicating strong execution and stable civilian infrastructure spending. A key risk is the $29.0 million G&C FAB-CON, LLC contract with the Department of Veterans Affairs, where only $6.6 million of $29.0 million has been outlayed over six years, signaling potential execution delays or funding constraints. No contracts are defense-related, limiting exposure to DOD budget cycles but tying performance to civilian agency appropriations and continuing resolution risks.

4 total filings
· daily

DHS Homeland Security Contracts — July 09, 2026

This digest covers $393.8 million in civilian Department of Homeland Security (DHS) contract obligations from July 9, 2026, with zero defense-related awards. The dominant theme is stable, labor-intensive support services and IT modernization across DHS agencies, led by CBP, USCIS, ICE, and TSA. The highest-conviction signal is a bullish $53.3 million Dell Federal Systems L.P. award for Coast Guard Microsoft licensing (potential $199.7 million total), indicating strong enterprise IT investment. Key risks include fixed-price execution pressure on GEO Group ($57.5 million) and moderate margin risk from time-and-materials pricing on Deloitte ($67.6 million) and Pluribus Digital ($64.5 million) contracts. Overall, the data points to steady civilian spending with limited disruptive growth catalysts for public companies, except for Dell and GEO Group.

8 total filings
· daily

VA Healthcare & Services Contracts — July 09, 2026

This digest covers a single civilian agency contract from the Department of Veterans Affairs (VA) totaling $28.97 million, with no defense-related awards. The sole award is a firm-fixed-price, Service Disabled Veteran Owned Small Business (SDVOSB) set-aside to G&C FAB-CON, LLC for design-build construction in South Florida, spanning 2018–2024. The highest-conviction signal is neutral: the contract indicates continued VA infrastructure spending and a competitive moat from the set-aside, but only $6.6 million (23%) has been outlayed, implying significant execution risk or delayed funding. Key watch items include the $22.3 million in unspent obligations and the fixed-price structure that could pressure margins if costs overrun.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 09, 2026

This digest covers $140.3 million in civilian HHS contracts awarded between 2018 and 2022, with zero defense exposure. The dominant theme is NIH/NIAID-funded infectious disease and structural biology research, accounting for $51.7 million across two nonprofit awards to Seattle Children's Hospital and Northwestern University, both cost-no-fee with no profit margin. The highest-conviction signal is Spero Therapeutics' $49.2 million BARDA cost-sharing contract, which provides long-term revenue through 2026 but carries medium pricing risk and shared financial burden. A key risk is the lack of competitive moat across all four awards, as none were sole-source or set-aside, leaving incumbents vulnerable at re-compete. Overall, the digest signals stable but low-margin civilian R&D funding, with no direct bullish catalysts for for-profit investors beyond Spero's potential revenue recognition.

4 total filings